Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › DR10624

DR10624

GLP-1/GCG/FGF21 · s.c. · Doer Biologics

Data cut 12 November 2026 · page built 16 November 2026 · 0 trial arms · 0 trials with results · 5 registered trials · see on the pipeline board

Summary

Also known as
Zhejiang Doer Biologics
Mechanism
GLP-1/GCG/FGF21
Route
s.c.
Company
Doer Biologics
Highest development stage
phase 3
Status (as of data cut)
Phase 3 in severe hypertriglyceridaemia; obesity/MASH in development verify
Next milestone
Phase 3 readout (sHTG)

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity0 no data
T2D0 no data
CV outcomes0 no data
CKD1 phase 2 / signalPhase 2 only
HFpEF0 no data
MASH1 phase 2 / signalPhase 2 only
Sleep apnoea0 no data
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

No trial arms with extracted efficacy or tolerability data yet.

Registered trials (5)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07848880
A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease
CKDPhase 2not yet recruiting2026-10 → 2028-04315not yet recruitingNCT07848880
NCT07680829
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
OtherPhase 3not yet recruiting2026-08 → 2030-06378not yet recruitingNCT07680829
NCT07693777
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
OtherPhase 3not yet recruiting2026-08 → 2029-02480not yet recruitingNCT07693777
NCT07024212
Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects
MASHPhase 2active not recruiting2025-04 → 2026-06110active not recruitingNCT07024212
NCT06555640
A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
OtherPhase 2completed2024-08 → 2025-0679Completed; results not in the atlas yetNCT06555640

Primary sources

No source recorded.

How to cite this page

Medical Adviser's Group. Incretin Atlas: DR10624. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/dr10624/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.